SCHEMBL3018372

SCHEMBL3018372

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
LMNA P02545 4/20 0.37
MAPK1 P28482 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HTR2A P28223 2/20 0.36
DRD2 P14416 1/20 0.36
HTR2C P28335 1/20 0.36
KCNH2 Q12809 1/20 0.36
TSHR P16473 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TP53 P04637 1/20 0.34
LSS P48449 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
GBA1 P04062 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017031 0.95 MAPT (0.42) MAPTLMNAMAPK1SMN1; SMN2HTR2A
SCHEMBL3016706 0.92 MAPT (0.37) MAPTLMNAMAPK1SMN1; SMN2HTR2A
SCHEMBL3011260 0.92 MAPT (0.42) MAPTLMNAMAPK1SMN1; SMN2HTR2A
SCHEMBL3006962 0.92 SMN1; SMN2 (0.35) MAPTLMNAMAPK1SMN1; SMN2HTR2A
SCHEMBL3001231 0.92 MAPT (0.42) MAPTLMNAMAPK1SMN1; SMN2HTR2A
SCHEMBL3017967 0.91 GBA1 (0.42) MAPTLMNAMAPK1SMN1; SMN2NPSR1
SCHEMBL3011786 0.90 MAPT (0.39) MAPTLMNAMAPK1SMN1; SMN2HTR2A
SCHEMBL3021897 0.90 HTR2A (0.45) MAPTLMNAMAPK1SMN1; SMN2HTR2A
SCHEMBL3013175 0.90 HRH3 (0.34) LMNAMAPK1SMN1; SMN2HTR2AHTR2C
SCHEMBL3010872 0.90 SMN1; SMN2 (0.41) MAPTLMNAMAPK1SMN1; SMN2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.